Generics Increasingly Used to Control Pharmacy Benefit Costs

March 24, 2008 (PLANSPONSOR.com) - Employers have been using cost sharing and tiered copayment structures to decrease pharmacy benefit costs, but Mercer has found employers are looking to other cost-reduction strategies such as more actively encouraging members to use generic drugs and mail-order plans to further reduce costs.

According to a Mercer press release, to encourage the use of generics, some employers require members to pay the difference in cost between a brand-name and a generic drug, in addition to the generic copay, if they request a brand drug when a generic equivalent is available. Nearly half of respondents to Mercer’s survey (49%) are using such a program, often called a Dispensed As Written (DAW) 2 penalty, and over a fourth (29%) reported using a tougher version, DAW 1, which imposes the penalty even if the physician requests the brand drug.

For more stories like this, sign up for the PLANSPONSOR NEWSDash daily newsletter.

Use of these penalties appears to be growing; an additional 9% of respondents said they will implement DAW 1 and 10% of respondents said they will implement DAW 2 within the next two years, the release said. Very few employers surveyed (4%) waived generic copays for a period of time as an incentive, but the use of targeted communications intended to educate members and/or prescribers about generic alternatives is increasing – 64% of respondents now use targeted communications, up from 48% in 2005.

The management of specialty or biotech drugs is also becoming increasingly important for employers, and a growing number of respondents say they have recently reviewed plan benefits and limits for specialty or biotech drugs (45% in 2007, up from 34% in 2005). Another 30% of respondents say they plan to review plan benefits for specialty drugs in 2008.

In 2007, prescription drug benefit costs rose 9.3% among large employers (those with 500 or more employees), while overall medical costs rose 5.1%, according to Mercer’s survey. Most employers use tiered copayments for their prescription drug benefit; the most common arrangement (72% at retail and 68% at mail order) is a three-tier structure with increasing copayment amounts for generic, formulary brand-name, and non-formulary brand-name drugs.

Among employers that offer a card plan, Mercer found 5% of employers with 500 or more employees and 10% of those with 20,000 or more employees have implemented four- or five-tier structures. More than a fifth of all large employers, and nearly half of those with 20,000 or more employees, require coinsurance for one or more drug categories.

Virtually all respondents provide a mail-order plan. In most plans (77%), members have a copay incentive to obtain drugs through the mail. A small portion of employers penalize members who do not use the mail-order plan for maintenance drugs. Six percent require an additional copay from members who continue to use retail pharmacies after a specified number of fills, and 10% discontinue retail coverage altogether.

Employers use targeted communication to educate members on the value of the mail-order plan (36%). Only 13% of respondents do not use any mail-order incentives or penalties.

Mercer also asked employers specifically about using incentives (by lowering or waiving drug copays/coinsurance for specific drug therapies) in pharmacy plan design to improve drug compliance and adherence. The survey findings suggest that this is still an emerging trend used only by a limited number of employers.

Only 6% of employers use financial incentives for diabetes treatment, the largest percentage in any therapeutic category. Over one-fourth (26%) of employers, however, are considering implementing a financial incentive program for diabetes therapy in the future, and approximately one-fourth are considering the same approach for other therapeutic classes used to treat chronic conditions (e.g., cholesterol, asthma, high blood pressure).

A slightly smaller percentage of employers now waive or reduce copays for specific classes of drugs, contingent upon the member's participation in a related disease management program. This incentive is most commonly used by employers for diabetes management (4% of employers report offering this benefit to employees). About a fourth of all respondents say they are considering this approach.

The survey was conducted in May 2007 as a follow up to Mercer's National Survey of Employer-Sponsored Health Plans 2006. All respondents to the 2006 survey with 500 or more employees were invited to participate and 508 submitted completed questionnaires.

«